Reported Earnings • Dec 02
Third quarter 2025 earnings released: ₪0.49 loss per share (vs ₪0.38 profit in 3Q 2024) Third quarter 2025 results: ₪0.49 loss per share (down from ₪0.38 profit in 3Q 2024). Revenue: ₪12.4m (up 29% from 3Q 2024). Net loss: ₪7.60m (down 229% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Announcement • Nov 17
Golden House Ltd, Annual General Meeting, Dec 22, 2025 Golden House Ltd, Annual General Meeting, Dec 22, 2025. Location: co. offices, Israel Reported Earnings • Aug 28
Second quarter 2025 earnings released: ₪0.043 loss per share (vs ₪0.14 loss in 2Q 2024) Second quarter 2025 results: ₪0.043 loss per share (improved from ₪0.14 loss in 2Q 2024). Revenue: ₪11.1m (up 22% from 2Q 2024). Net loss: ₪665.0k (loss narrowed 70% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. New Risk • May 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 10% Last year net profit margin: 36% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Dividend is not well covered by earnings (478% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Market cap is less than US$100m (₪197.4m market cap, or US$56.6m). Reported Earnings • May 30
First quarter 2025 earnings released: EPS: ₪0.14 (vs ₪0.14 in 1Q 2024) First quarter 2025 results: EPS: ₪0.14 (up from ₪0.14 in 1Q 2024). Revenue: ₪11.3m (up 15% from 1Q 2024). Net income: ₪2.24m (up 2.8% from 1Q 2024). Profit margin: 20% (down from 22% in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has remained flat, which means it is well ahead of earnings. New Risk • Apr 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Market cap is less than US$100m (₪246.1m market cap, or US$65.7m). New Risk • Apr 01
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 76% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Reported Earnings • Apr 01
Full year 2024 earnings released: EPS: ₪0.27 (vs ₪1.04 in FY 2023) Full year 2024 results: EPS: ₪0.27 (down from ₪1.04 in FY 2023). Revenue: ₪39.8m (down 35% from FY 2023). Net income: ₪4.12m (down 75% from FY 2023). Profit margin: 10% (down from 26% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₪28.82, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 9x in the Healthcare industry in Israel. Total returns to shareholders of 125% over the past three years. Buy Or Sell Opportunity • Mar 06
Now 22% undervalued Over the last 90 days, the stock has risen 21% to ₪26.52. The fair value is estimated to be ₪33.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.0% over the last 3 years. Earnings per share has declined by 6.5%. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₪26.53, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 108% over the past three years. New Risk • Feb 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change). Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₪23.19, the stock trades at a trailing P/E ratio of 7.5x. Average trailing P/E is 21x in the Healthcare industry in Asia. Total returns to shareholders of 76% over the past three years. Reported Earnings • Dec 01
Third quarter 2024 earnings released: EPS: ₪0.38 (vs ₪1.27 loss in 3Q 2023) Third quarter 2024 results: EPS: ₪0.38 (up from ₪1.27 loss in 3Q 2023). Revenue: ₪9.62m (down 37% from 3Q 2023). Net income: ₪5.91m (up ₪25.7m from 3Q 2023). Profit margin: 62% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Announcement • Nov 05
Golden House Ltd, Annual General Meeting, Dec 11, 2024 Golden House Ltd, Annual General Meeting, Dec 11, 2024. Location: co. offices, Israel Reported Earnings • Sep 03
Second quarter 2024 earnings released: ₪0.14 loss per share (vs ₪0.19 profit in 2Q 2023) Second quarter 2024 results: ₪0.14 loss per share (down from ₪0.19 profit in 2Q 2023). Revenue: ₪9.09m (down 36% from 2Q 2023). Net loss: ₪2.21m (down 175% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₪21.67, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 23x in the Healthcare industry in Asia. Total returns to shareholders of 65% over the past three years. Reported Earnings • Jun 04
First quarter 2024 earnings released: EPS: ₪0.42 (vs ₪0.36 in 1Q 2023) First quarter 2024 results: EPS: ₪0.42 (up from ₪0.36 in 1Q 2023). Revenue: ₪11.9m (down 27% from 1Q 2023). Net income: ₪6.41m (up 16% from 1Q 2023). Profit margin: 54% (up from 34% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 11% per year. Reported Earnings • Apr 03
Full year 2023 earnings released: EPS: ₪1.04 (vs ₪5.38 in FY 2022) Full year 2023 results: EPS: ₪1.04 (down from ₪5.38 in FY 2022). Revenue: ₪61.1m (down 2.2% from FY 2022). Net income: ₪16.1m (down 81% from FY 2022). Profit margin: 26% (down from 134% in FY 2022). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₪20.16, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 11x in the Healthcare industry in Israel. Total returns to shareholders of 57% over the past three years. New Risk • Feb 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Dividend is not well covered by earnings and cash flows. Payout ratio: 108% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (29% net profit margin). Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₪17.97, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 10x in the Healthcare industry in Israel. Total returns to shareholders of 41% over the past three years. New Risk • Jan 01
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (29% net profit margin). Market cap is less than US$100m (₪245.7m market cap, or US$68.2m). Reported Earnings • Jan 01
Third quarter 2023 earnings released: ₪1.27 loss per share (vs ₪0.19 loss in 3Q 2022) Third quarter 2023 results: ₪1.27 loss per share (further deteriorated from ₪0.19 loss in 3Q 2022). Revenue: ₪15.2m (up 10% from 3Q 2022). Net loss: ₪19.8m (loss widened ₪16.8m from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₪11.38, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 8x in the Healthcare industry in Israel. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Oct 01
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₪14.35, the stock trades at a trailing P/E ratio of 6.3x. Average trailing P/E is 9x in the Healthcare industry in Israel. Total returns to shareholders of 44% over the past three years. Valuation Update With 7 Day Price Move • Sep 07
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₪12.54, the stock trades at a trailing P/E ratio of 5.5x. Average trailing P/E is 7x in the Healthcare industry in Israel. Total returns to shareholders of 17% over the past three years. New Risk • Sep 02
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 58% Last year net profit margin: 103% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (58% net profit margin). Market cap is less than US$100m (₪161.0m market cap, or US$42.3m). Reported Earnings • Sep 02
Second quarter 2023 earnings released: EPS: ₪0.19 (vs ₪0.55 in 2Q 2022) Second quarter 2023 results: EPS: ₪0.19 (down from ₪0.55 in 2Q 2022). Revenue: ₪14.1m (down 5.4% from 2Q 2022). Net income: ₪2.97m (down 66% from 2Q 2022). Profit margin: 21% (down from 58% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Jun 13
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 4.2% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (4.2% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₪201.1m market cap, or US$56.5m). Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₪13.59, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 8x in the Healthcare industry in Israel. Total returns to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₪11.55, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 9x in the Healthcare industry in Israel. Total loss to shareholders of 3.5% over the past three years. Reported Earnings • Dec 04
Third quarter 2022 earnings released: ₪0.19 loss per share (vs ₪0.001 profit in 3Q 2021) Third quarter 2022 results: ₪0.19 loss per share (down from ₪0.001 profit in 3Q 2021). Revenue: ₪13.8m (down 5.3% from 3Q 2021). Net loss: ₪2.94m (down ₪2.96m from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Amir Yehuda was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Amir Yehuda was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improved over the past week After last week's 15% share price gain to ₪13.24, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 17x in the Healthcare industry in Asia. Total returns to shareholders of 4.3% over the past three years. Reported Earnings • Jun 02
First quarter 2022 earnings released: EPS: ₪3.10 (vs ₪0.50 in 1Q 2021) First quarter 2022 results: EPS: ₪3.10 (up from ₪0.50 in 1Q 2021). Revenue: ₪16.6m (up 26% from 1Q 2021). Net income: ₪48.2m (up ₪40.4m from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Dec 04
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Third quarter 2021 results: EPS: ₪0.001 (down from ₪0.56 in 3Q 2020). Revenue: ₪14.6m (down 19% from 3Q 2020). Net income: ₪16.0k (down 100% from 3Q 2020). Profit margin: 0.1% (down from 48% in 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Reported Earnings • Sep 04
Second quarter 2021 earnings released: ₪0.18 loss per share (vs ₪0.039 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: ₪13.1m (down 4.4% from 2Q 2020). Net loss: ₪2.74m (down ₪3.36m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment improved over the past week After last week's 18% share price gain to ₪14.40, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 26x in the Healthcare industry in Asia. Total loss to shareholders of 2.0% over the past three years. Is New 90 Day High Low • Mar 08
New 90-day low: ₪12.19 The company is down 15% from its price of ₪14.29 on 08 December 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is flat over the same period. Is New 90 Day High Low • Nov 19
New 90-day high: ₪12.49 The company is up 6.0% from its price of ₪11.82 on 20 August 2020. The Israeli market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 7.0% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: ₪9.90 The company is down 7.0% from its price of ₪10.60 on 16 July 2020. The Israeli market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 10.0% over the same period.